Novel Second-Line Treatment Strategies in Endometroid Adenocarcinoma

According to the developer, a future approval of dostarlimab for this indication would bring the first meaningful frontline treatment for this patient population in decades.

In season 3, episode 7 of Targeted Talks, John Nakayama, MD, discusses updates in the endometrial cancer treatment landscape.

A subgroup analysis of ENGOT-EN6-NSGO/GOG-3031/RUBY has displayed positivity efficacy in patients with advanced/recurrent endometrial cancer.

The combination of lenvatinib and pembrolizumab continued to show benefits in efficacy vs chemotherapy among patients with endometrial cancer treated in Study 309/KEYNOTE-775.

A trial of TOS-358, a first-in-class covalent PI3Kα inhibitor, for various solid tumors dosed its first patient.

An artificial intelligence model has been shown to predict the risk of low and high distant recurrence in patients with endometrial cancer.